Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $1,303,000.00 in Stock
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $1,303,000.00 in Stock
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) insider Gary Charles Robb sold 50,000 shares of Corcept Therapeutics stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $26.06, for a total transaction of $1,303,000.00. Following the completion of the transaction, the insider now owns 49,544 shares in the company, valued at $1,291,116.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Corcept治療公司(納斯達克:CORT-GET評級)內部人Gary Charles Robb在9月7日星期三的一筆交易中出售了50,000股Corcept治療公司的股票。這些股票以26.06美元的平均價格出售,總成交額為1,303,000.00美元。交易完成後,這位內部人士現在擁有該公司49,544股,價值1,291,116.64美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個超級鏈接獲得。
Gary Charles Robb also recently made the following trade(s):
加里·查爾斯·羅布最近還進行了以下交易:
- On Wednesday, July 6th, Gary Charles Robb sold 45,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $26.00, for a total transaction of $1,170,000.00.
- 7月6日星期三,加里·查爾斯·羅布出售了45,000股Corcept治療公司的股票。該股以26.00美元的平均價格出售,總成交金額為117萬美元。
Corcept Therapeutics Trading Up 1.1 %
Corcept Treateutics股價上漲1.1%
Shares of NASDAQ CORT traded up $0.28 on Friday, reaching $26.43. 5,215 shares of the company traded hands, compared to its average volume of 477,887. Corcept Therapeutics Incorporated has a fifty-two week low of $15.82 and a fifty-two week high of $29.93. The company has a 50 day moving average of $27.12 and a 200 day moving average of $24.06. The stock has a market capitalization of $2.83 billion, a PE ratio of 27.82, a P/E/G ratio of 2.65 and a beta of 0.56.
週五,納斯達克的股價上漲了0.28美元,達到26.43美元。該公司有5,215股易手,而其平均成交量為477,887股。Corcept治療公司的股價為15.82美元,為52周低點,52周高點為29.93美元。該公司的50日移動均線切入位在27.12美元,200日移動均線切入位在24.06美元。該股市值28.3億美元,市盈率27.82倍,市盈率2.65倍,貝塔係數0.56。
Analyst Ratings Changes
分析師評級發生變化
Institutional Trading of Corcept Therapeutics
Corcept治療藥物的制度性交易
A number of institutional investors and hedge funds have recently bought and sold shares of CORT. Gladius Capital Management LP acquired a new stake in Corcept Therapeutics during the 2nd quarter worth approximately $31,000. Financial Management Professionals Inc. acquired a new stake in Corcept Therapeutics during the 2nd quarter worth approximately $47,000. Lazard Asset Management LLC increased its position in Corcept Therapeutics by 2,286.8% during the 2nd quarter. Lazard Asset Management LLC now owns 2,530 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 2,424 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Corcept Therapeutics during the 2nd quarter worth approximately $76,000. Finally, Point72 Hong Kong Ltd increased its position in Corcept Therapeutics by 283.1% during the 4th quarter. Point72 Hong Kong Ltd now owns 7,707 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 5,695 shares in the last quarter. Institutional investors and hedge funds own 78.46% of the company's stock.
一些機構投資者和對衝基金最近買賣了Cort的股票。Gladius Capital Management LP在第二季度收購了Corcept Treeutics的新股份,價值約3.1萬美元。財務管理專業公司在第二季度收購了Corcept Treateutics公司價值約4.7萬美元的新股份。Lazard Asset Management LLC在第二季度將其在Corcept Treateutics的頭寸增加了2286.8%。Lazard Asset Management LLC在上個季度又購買了2424股,現在擁有2530股這家生物技術公司的股票,價值6萬美元。Quantbot Technologies LP在第二季度收購了Corcept Treateutics的新股份,價值約7.6萬美元。最後,Point72 Hong Kong Ltd在第四季度將其在Corcept Treeutics的持倉增加了283.1%。Point72 Hong Kong Ltd在上個季度額外購買了5695股後,現在擁有這家生物技術公司7,707股股票,價值15.3萬美元。機構投資者和對衝基金持有該公司78.46%的股票。
Corcept Therapeutics Company Profile
Corcept治療公司簡介
(Get Rating)
(獲取評級)
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Corcept Treateutics公司在美國發現、開發和銷售治療嚴重代謝、腫瘤和神經精神疾病的藥物。該公司提供Korlym(米非司酮)片劑,作為每日一次的口服藥物,用於治療患有內源性庫欣綜合徵的成年患者繼發於高皮質醇血癥的高血糖,這些患者患有2型糖尿病或葡萄糖耐受不良,且手術失敗或不適合手術。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- 免費獲取StockNews.com關於Corcept治療(CORT)的研究報告
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
- 希捷科技的宿醉何時才能結束?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Corcept治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Corcept Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。